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Abstract
The cellular adhesion molecule LFA-1 and its ICAM-1 ligand play an important role in promoting HIV-1 infectivity and
transmission. These molecules are present on the envelope of HIV-1 virions and are integral components of the HIV
virological synapse. However, cellular activation is required to convert LFA-1 to the active conformation that has high
affinity binding for ICAM-1. This study evaluates whether such activation can be induced by HIV itself. The data show that
HIV-1 gp120 was sufficient to trigger LFA-1 activation in fully quiescent naı ¨ve CD4 T cells in a CD4-dependent manner, and
these CD4 T cells became more susceptible to killing by LtxA, a bacterial leukotoxin that preferentially targets leukocytes
expressing high levels of the active LFA-1. Moreover, virus p24-expressing CD4 T cells in the peripheral blood of HIV-infected
subjects were found to have higher levels of surface LFA-1, and LtxA treatment led to significant reduction of the viral DNA
burden. These results demonstrate for the first time the ability of HIV to directly induce LFA-1 activation on CD4 T cells.
Although LFA-1 activation may enhance HIV infectivity and transmission, it also renders the cells more susceptible to an
LFA-1-targeting bacterial toxin, which may be harnessed as a novel therapeutic strategy to deplete virus reservoir in HIV-
infected individuals.
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Introduction
Efficient progression of the different steps in human immunode-
ficiency virus (HIV) replication, from virus-cell attachment to virus
progeny production, is tightly linked to the activation state of the
host CD4 T cells. T cell activation impacts on the initial HIV
interaction with the target CD4 T cells through the involvement of
adhesion molecule leukocyte functon antigen-1 (LFA-1) and its
inter-cellular adhesion molecule-1 (ICAM-1) ligand [1,2]. LFA-1
and ICAM-1 are incorporated into the envelope of HIV-1 virions
budding from activated primary CD4 T cells that support
productive virus replication [3,4]. HIV-1 virions bearing ICAM-1
are more infectious than their ICAM-1-negative counterparts, due
to enhanced virus binding to LFA-1-bearing target cells [5,6].
Therefore, LFA-1 expression on target cells increases susceptibility
to HIV-1 infection via cell-free virions [1,7,8]. LFA-1 and ICAM-1
also play a critical role in cell-cell transmission as these adhesion
molecules are integral components of the HIV-1 virological synapse
[9,10], which serves as a major mode for HIV-1 transmission from
cell to cell. Furthermore, ICAM-1 expression on HIV-1 virions
alone or in combination with LFA-1 on the target cells increases
HIV-1 resistance to neutralizing antibodies [2,11–13]. One should
note, however, that LFA-1 must first be activated to mediate its
function as the receptor for ICAM-1 [14]. The inactive form binds
poorly to its ligand, but upon T cell activation, LFA-1 undergoes
conformationalchangesthatincreaseitsaffinityforICAM-1.Under
physiologic condition, LFA-1 activation results from TCR engage-
ment of the specific peptide-MHC complex and inside-out signaling
induced as part of the canonical TCR activation signals [15].
Activation of host T cells is also critical for the steps of virus life cycle
subsequent to virus attachment and entry. Quiescent CD4 T cells at
G0/1a phase are refractory to infection, due to the slow kinetics of
the early steps of the virus replication including the inefficient
reverse transcription, and cellular activation that propels the cells
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proceed [16]. After the integrated provirus is established, virus gene
expression is again regulated by cellular activation via the
participation of cellular nuclear factors NF-kB and/or NFAT
[17]. The activation of these transcription factors is a downstream 2
event of the TCR-induced signaling cascade; NF-kB is activated
via the diacylglycerol/protein kinase C pathway, while NFAT
activation is induced by the IP3/calcineurin pathway [18].
Considering the importance of host T cell activation in HIV
replication and the advantageous contributions of LFA-1-ICAM-1
interactions to HIV-1 infectivity, we postulate that HIV via its
envelope protein gp120exploitsthe T cellactivation mechanismand
triggers LFA-1 activation in order to promote its infectivity,
replication, transmission, and resistance from anti-viral immunity.
HIV gp120 binding to CD4 and/or the chemokine receptor has
been shown to trigger activation of different signaling pathways and
virus replication in the absence of conventional activation markers
[19–24]. Our previous studies have also demonstrated that the
interaction of surface-bound gp120 with CD4 on activated primary
CD4 T cells induces activation of some components of the T cell
signaling machinery, albeit without stimulating full T cell activation
[25]. Importantly, this cellular activation is sufficient to cause
rearrangement of LFA-1-ICAM-1 interactions leading to the
formation of an adhesive ring resembling a peripheral supramolec-
ular activation cluster of the T cell immunological synapse [25,26].
LFA-1 activation has also been reported to result from gp120
engagement of the active form of the integrin a4b7o nr e t i n o i ca c i d -
treated CD4 T cells [27]. Nevertheless, the capacity of gp120 to fully
activate LFA-1from its inactive statehasnot been evaluateddirectly.
In the present study, we investigated gp120-induced LFA-1
activationbymonitoringtheinteractionofnaı ¨verestingCD4Tcells
that express LFA-1 inits inactiveform with ICAM-1 inthe presence
of gp120 bound onto laterally mobile planar bilayers. LFA-1
expression was also monitored on CD4 T cells with active HIV
infection from the peripheral blood of HIV-infected subjects. We
further confirmed virus-associated LFA-1 activation by utilizing a
leukotoxin (LtxA) from an oral bacterium Aggregatibacter actinomyce-
temcomitans that is known to preferentially target cells expressing the
active form of LFA-1 [28]. LtxA is effective against LFA-1-
expressing leukocytes of humans and Old World primates. A single
intravenous administration of LtxA in a healthy uninfected rhesus
macaquehas been showntocauseasubstantialbuttransientdrop of
white blood cell counts in the peripheral blood for ,12 hrs without
any effects on red blood cell, platelet, and hemoglobin values and
without any signs of liver toxicity or kidney dysfunction [28]. In
addition, LtxA was highly effective at treating leukemia in a
humanized SCID mouse model [28]. Nevertheless, the effects of
LtxA on cellular reservoirs of HIV-1 remain to be determined. This
study demonstrates that the presence of activated LFA-1 was
characteristic of CD4 T cells which were exposed to HIV envelope
in vitro and CD4 T cells that supported HIV replication in the
peripheral blood of HIV-1 infected subjects. These virus-associated
CD4 T cells were sensitive to killing by LFA-1-specific LtxA. This
study presents initial data for the potential development of a
bacterial leukotoxin as a therapeutic reagent to deplete host cells
recently exposed to or already infected with HIV to reduce the
overall viral burden in HIV-infected individuals.
Results
The interaction of CD4 T cells with HIV-1 gp120 on bilayers
triggers LFA-1 activation and supramolecular re-organization
The virus envelope glycoprotein gp120 has been shown to
induce CD4 T cell activation [19,22–25], but there has not been
any direct evidence of gp120 to activate LFA-1 on completely
quiescent CD4 T cells. In a recent study, we demonstrated that the
interaction of CD4 T cells with gp120 on a glass-supported
laterally-mobile planar bilayer causes phosphorylation of many
signaling molecules involved in TCR-induced activation, albeit in
the absence of full T cell activation [25]. However, because the
CD4 T cells tested in that study were already activated with anti-
CD3 and anti-CD28 antibodies, their LFA-1 was in the high
affinity state and therefore the capacity of gp120 to trigger LFA-1
activation could not be studied. To address this question, we
analyzed the interaction of resting naı ¨ve CD4 T cells obtained ex
vivo from the peripheral blood of healthy HIV-seronegative
donors with gp120 and ICAM-1 on glass-supported planar lipid
bilayers. The bilayers served as an experimental model mimicking
the virion surface or the infected cell surface. To discern changes
in cellular morphology and molecular organization, the bilayers
were loaded with Alexa Fluor 488-labeled gp120 and Cy5-labeled
ICAM-1. For comparison, bilayers were also prepared with Cy5-
labeled ICAM-1 alone. After the cells were added onto the
bilayers, live images were acquired for up to 1 hr using multicolor
total internal reflectance fluorescent (TIRF) microscopy.
Naı ¨ve peripheral CD4 T cells express LFA-1 in the inactive
states with low affinity for ICAM-1. Indeed, naı ¨ve CD4 T cells
enriched from PBMCs of HIV-seronegative donors were CD4+,
CD3+, CD45RA+, CD45R0- and were not stained with mAb
NKI-L16 (Figure S1), which binds to an epitope on the active-
state, extended conformation of the LFA-1 a subunit [29]. By
contrast, this same mAb stained 11.6% of cells in the
unfractionated PBMCs.
On bilayers containing ICAM-1 alone, these naı ¨ve cells rarely
formed contact with the bilayers and if they did, the contact was
transient and did not cause any ICAM-1 accumulation (Figure 1).
However, when these cells were introduced onto bilayers
containing gp120 and ICAM-1, cells established gp120 contacts
within the first 5–10 min and 10 min later started forming ICAM-
1 contact (Figure 2A). About 40% of the cells established stable
LFA-1-ICAM-1-mediated adhesion (Figure 2B). In addition,
supramolecular rearrangements of both gp120 and ICAM-1 were
observed: gp120 accumulated into a central cluster and ICAM-1
assembled into a ring, which was either symmetrical (for 20% of
the cells; Figure 2B top) or asymmetrical (for another 20%;
Figure 2B bottom), around the central gp120 cluster. Once
formed, the morphology was maintained for the duration of the
experiment (1 hr). The remaining cells contacted gp120 but did
not accumulate ICAM-1 or did not make stable ICAM-1 contact
(not shown). The LFA-1-ICAM-1 interaction and rearrangement
were triggered specifically by gp120 binding to its receptors on the
T cell surface, since pre-treatment with mAbs to the CD4-binding
site (654) substantially reduced not only the numbers of cells
forming gp120 contact (Figure 2C, left graph), but also ICAM-1
contact (Figure 2C, right graph). MAb 2219 against the V3 loop,
which is involved in binding the chemokine receptor, also
decreased both gp120 and ICAM-1 contacts, although it was
not as effective as the anti-CD4 binding site mAb. A mAb to the
N-terminus of gp120 (EH21) which does not participate in CD4 or
the chemokine receptor binding had no effect as both gp120 and
ICAM-1 contacts were comparable to those of untreated controls.
To determine whether engagement of CD4 alone is sufficient to
induce LFA-1 activation, we introduced naı ¨ve CD4 T cells onto
bilayers containing an anti-CD4 mAb and ICAM-1. About 28%
of the cells established contact with the mAb and ICAM-1, but
ICAM-1 accumulation assembled mainly into an asymmetrical
ring (Figure 2D). Only 1.75% of the cells formed symmetrical
ICAM-1 rings, which were transient, lasting only two minutes.
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CD4 mAb and had no ICAM-1 accumulation. The remaining
cells had neither ICAM-1 nor anti-CD4 mAb contacts. For
comparison, LFA-1 activation of naı ¨ve CD4 T cells as a result of
the physiologic T cell receptor (TCR) engagement was also
evaluated by monitoring the interaction of the naı ¨ve cells with
bilayers containing anti-CD3 mAb and ICAM-1. The vast
majority of the cells displayed CD3 and ICAM-1 supramolecular
arrangement; 40% formed the conventional immunological
synapse with a central CD3 cluster and a symmetrical ICAM-1
ring, and 46% had an asymmetrical ICAM-1 ring (Figure 2E).
Importantly, these synapses were very stable, lasting throughout
the entire experiment (45 min), similar to those induced upon
interaction with gp120 but not with the anti-CD4 mAb. These
data indicate that gp120 binding to its receptor CD4 triggers LFA-
1 activation and supramolecular rearrangement, as revealed by
formation of synapses with stable LFA-1-ICAM-1 interactions.
However, this LFA-1 activation is not as robust as that triggered
via the T cell receptor. CD4 engagement by antibody also weakly
induces LFA-1 activation, but generates a distinct pattern of LFA-
1-ICAM-1 supramolecular organization. Hence, the effect of
gp120 on naı ¨ve CD4 T cells is unique and cannot be fully
mimicked by an anti-CD4 mAb.
CD4 T cells exposed to surface-bound gp120 are more
susceptible to killing by the LFA-1-targeting bacterial
leukotoxin (LtxA)
LFA-1 activation is triggered by gp120 upon binding to CD4 T
cells therefore, we surmise that these cells should become highly
susceptible to LtxA, a bacterial leukotoxin that is known to
preferentially kill leukocytes with high levels of the activated form
of LFA-1 [28]. To examine this idea, we incubated resting CD4 T
cells from healthy uninfected donors on tissue culture wells coated
with or without gp120 and then treated them with different
concentrationsofLtxA.After20 hrs,cellviabilitywasdeterminedby
measurement of cellular ATP. A mutant gp120 protein lacking the
ability to bind CD4 and the chemokine receptors (CD4bs- V3-) was
tested as a control. Data in Figure 3A shows that CD4 T cells
interacting with gp120 were more susceptible to LtxA than cells
incubated with the mutated gp120 or no gp120. The increased cell
death was apparent at different concentrations of LtxA. The 50%
effective dose (ED50) of LtxA against gp120-treated CD4 T cells was
263 ng/ml, while the ED50 of LtxA against untreated cells and
mutantgp120-treatedcellswere577 and540 ng/ml,respectively.In
other experiments with cells from two different donors, ED50 of
LtxA against gp120-treated CD4 T cells ranged from 150 to
276 ng/ml (mean and standard deviation, 213 +/2 89 ng/ml).
Treatment with gp120 without LtxA had no significant effect on the
CD4Tcellviability(Figure3A).TheenhancedsusceptibilitytoLtxA
as a result of gp120 interaction was modest when compared with
canonical T cell activation by surface-bound anti-CD3 and anti-
CD28 antibodies (Figure 3B). Stimulation with the anti-CD3+CD28
antibodies increased cell susceptibility to LtxA by .100 fold (ED50
of 5 ng/ml). This confirms our previous data showing the strong
preference of LtxA for active LFA-1-expressing T cells [28].
To verify the specificity of the gp120 effect and assess the
molecular interactions involved, we first measured LtxA suscep-
tibility of naı ¨ve CD4 T cells treated with the anti-CD4 antibody.
The data show that naı ¨ve CD4 T cells interacting with anti-CD4
antibody coated on wells also became more susceptible to LtxA
(Figure 3B), indicating the contribution of CD4 engagement in
LFA-1 activation. The mean ED50 of LtxA against anti-CD4-
antibody-treated cells was 180 ng/ml (standard deviation, 57 ng/
ml), comparable to that against gp120-treated cells. Subsequently,
we used mAbs against different gp120 epitopes or small molecules
that block gp120 interaction with CD4 or the chemokine receptors
and measured their effects on LtxA susceptibility of gp120-treated
cells. The enhanced susceptibility to LtxA was abrogated by mAb
654 or soluble CD4, both of which blocks gp120-CD4 interaction,
while mAb against the V3 loop of gp120 (694) or chemokine
Figure 1. Naı ¨ve CD4 T cells do not form stable interaction with the ICAM-1 bilayer. The naı ¨ve CD4 T cells were injected onto a bilayer
containing only ICAM-1 and monitored over one hour for the presence of cells (bright-field panels), contact with the bilayer (interference reflection
microscopy (IRM) panels) and contact with ICAM-1 (ICAM-1 panel). The same representative field is shown at the indicated time points. Thin black
arrows show the cells that interacted transiently with the bilayers at 15 min but had no ICAM-1 accumulation and migrated by 30 min. Three new
cells interacting with the bilayer at 50 min were also observed and indicated by thick white arrows; again these cells made no ICAM-1 contact and did
not induce any ICAM-1 aggregation.
doi:10.1371/journal.pone.0023202.g001
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PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e23202Figure 2. HIV gp120 interaction with quiescent naı ¨ve CD4 T cells triggers LFA-1 activation and supramolecular rearrangement. (A)
Naı ¨ve CD4 T cells establish LFA-1-ICAM-1 interaction upon gp120 binding. The naı ¨ve CD4 T cells purified by negative selection from ex vivo HIV-
seronegative PBMCs were introduced to a bilayer containing Alexa Fluor 488-labeled gp120 and Cy5-labeled ICAM-1, and images were acquired over
an hour. Images from one representative cell to show the dynamics of cell interaction with gp120 and ICAM-1 over time are presented. Top panels
show gp120 contact the cell made at the indicated time points, middle panels show ICAM-1 contact, and bottom panels display merged images
(gp120 in green, ICAM-1 in red). (B) Morphology of ICAM-1 contact areas made upon the interaction of naı ¨ve CD4 T cells with gp120 and ICAM-1 on
the bilayers. Images of representative cells and the percentages of cells that form symmetrical (top panel) or asymmetrical (bottom panel) ICAM-1
rings are shown. gp120 was added onto the bilayers at a density of 200 to 250 molecules/mm
2. (C) Naı ¨ve T cells were added to the bilayers in the
presence of an anti-gp120 mAb that blocks gp120-CD4 interaction (654), an anti-V3 mAb that interferes with gp120 binding to the chemokine
receptor (2219), or a mAb to the N-terminus of gp120 (EH21) that does not affect gp120 interaction with its receptors. The percentages of cells
making gp120-positive (left) and ICAM-1-positive (right) contacts out of the total number of cells seen in the fields were calculated. The MAbs were
used at 20 mg/ml. The graphs represent the averages +/- SEM of three independent experiments. Statistical analysis was done by one-sided Student’s
t test. (D and E) Morphology of ICAM-1 contact areas made upon the interaction of naı ¨ve CD4 T cells with bilayers containing ICAM-1 and monoclonal
antibodies to CD4 (OKT4) or CD3 (OKT3). The percentages of cells that form symmetrical (top panel) or asymmetrical (bottom panel) ICAM-1 rings are
shown for comparison with those observed in gp120 + ICAM-1 bilayers (B). The densities of OKT4 and OKT3 on the bilayer were 250 molecules/mm
2.
doi:10.1371/journal.pone.0023202.g002
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PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23202Figure 3. The interaction of quiescent CD4 T cells with surface-bound gp120 renders the cells more susceptible to leukotoxin LtxA.
(A) CD4 T cells purified ex vivo from HIV-seronegative PBMCs were incubated on wells coated with 10 mg/ml wild type gp120 (JRFL), mutant gp120
(JRFL) lacking CD4-binding site and V3, or no gp120 and then treated with titrated amounts of LtxA. (B) For comparison, CD4 T cells were also
incubated on wells coated with anti-CD3 and anti-CD28 antibodies (5 mg/ml each) or anti-CD4 antibody (10 mg/ml) and treated with the designated
concentrations of LtxA. (C) CD4 T cells were incubated on gp120-coated wells in the presence of monoclonal antibodies (mAb) against the CD4-
binding site (anti-CD4bs) or the V3 loop of gp120, soluble CD4 (sCD4), or the chemokine receptor antagonists, and then treated with titrated
amounts of LtxA. (D) R5 gp120 (JRFL) or X4 gp120 (HXB2) was used to coat the wells, incubated with CD4 T cells, and tested for induction of LtxA-
mediated killing. In A, C, and D, the gp120 proteins were coated on microtiter wells at 10 mg/ml. (E) CD4 T cells were treated with soluble gp120
(10 mg/ml), anti-CD3/anti-CD28 coated on wells, or gp120 coated on wells, prior to addition of LtxA. After incubation with LtxA for 20 hrs, the cell
viability was measured based on cellular ATP. Data from one of two or more representative experiments are shown. The mean and standard deviation
values from duplicate wells are presented.
doi:10.1371/journal.pone.0023202.g003
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[CCR5-specific]) had minimal effects (Figure 3C). These results
consistently demonstrate the importance of gp120 binding to
CD4, but not the chemokine receptor, in triggering LFA-1
activation.
We further demonstrate that both R5 and X4 gp120 were able
to enhance susceptibility of naı ¨ve CD4 T cells to LtxA (Figure 3D).
In the absence of LtxA, R5 or X4 gp120 did not reduce CD4 T
cell viability. However, the enhanced killing was induced only
when the cells interacted with gp120 bound on the well surface;
soluble gp120 did not have the same effect (Figure 3E), indicating
that gp120-mediated crosslinking of CD4 is essential for LFA-1
activation that renders the CD4 T cells more susceptible to killing
by LFA-1-specific LtxA. CD4 T cells activated by surface-bound
anti-CD3 and anti-CD28 antibodies were used as a control, and
nearly 100% of these cells were killed by LtxA at the
concentrations tested (Figure 3E). These data demonstrate that
gp120 binding to quiescent naı ¨ve CD4 T cells renders the cells
more susceptible to LtxA due to LFA-1 activation as a result of
CD4 cross-linking, although the gp120-induced activity is not as
potent as that triggered by TCR engagement.
Viral p24-producing CD4 T cells in the peripheral blood
of HIV-infected subjects display higher levels of total and
active LFA-1
To evaluate LFA-1 expression on HIV-infected CD4 T cells in
the peripheral blood, we analyzed ex vivo PBMCs from two
viremic untreated HIV-infected subjects (PS05 and PS07) who
were asymptomatic and had CD4 counts of .450. Virus-infected
cells were detected by flow cytometry following intracellular
staining with an anti-p24 monoclonal antibody and surface
staining with monoclonal antibodies to the phenotype markers
(CD3 and CD8) and LFA-1. The dot plots in Figure 4A shows that
0.57% and 0.52% of p24+ CD3+ CD8- T cells were detected in
subjects PS05 and PS07, respectively. The p24+ gating is based on
the p24 staining of HIV-seronegative PBMCs tested in parallel in
each assay (Figure S2-A). When the total LFA-1 expression of
p24+ and p24- cells was compared, higher levels were detected on
the p24+ cell population than on the p24- cell population from the
same subjects. The higher LFA-1 expression levels were specific as
no increase in CD3 expression was observed on p24+ cells as
compared to p24- cells (Figure S2-B). PBMCs from two additional
viremic HIV-infected subjects (PS15 and PS16) were also stained
with mAb NKI-L16, which is specific for the active LFA-1 a
subunit [29]. The data in Figure 4B show that p24+ CD4 T cells
indeed expressed higher levels of active LFA-1 than p24- cells,
indicative of the activated state of HIV-infected CD4 T cells
producing viral p24 antigens in the peripheral blood.
LtxA treatment of HIV-infected PBMCs decreases HIV
DNA levels
Considering that CD4 T cells supporting active HIV infection
have higher levels of surface LFA-1 expression and that LtxA has
been shown to preferentially target activated CD4 T cells
expressing higher levels of LFA-1, we examined whether LtxA
treatment can target the infected CD4 T cells and reduce the levels
of viral DNA in the PBMCs of HIV-infected individuals. PBMCs
from two viremic HIV-seropositive subjects (PS05 and PS14) were
treated with a single dose of LtxA (7.8 mg/ml) for 20 hrs, and the
amounts of viral DNA and b-actin quantified by real time PCR.
The data in Figure 4C show that 2682 and 1223 copies of viral
DNA were initially detected in PBMCs of subjects PS05
(,2.5610
5 cells) and PS014 (,1.2610
5 cells), respectively, and
LtxA treatment reduced viral DNA by 84% and 39%. The
reduction of viral DNA was accompanied by comparable
reduction in b-actin copy numbers (Figure S3). Since virus
infected cells constituted only ,0.5% of total peripheral CD4 T
cells, these data indicate that the cells targeted by LtxA are likely
to include uninfected bystanders as well as HIV infected cells.
Overall, this study indicates that LtxA may be an effective
compound for removing cells bearing HIV-1 and reducing viral
DNA loads but LtxA can also affect bystander uninfected cells,
although the biologic consequences of such depletion remains to
be investigated.
Discussion
Unlike CD4 and the chemokine receptors, LFA-1 and ICAM-1
are not absolutely required for HIV infection. However, the
important role of these cellular adhesion molecules in enhancing
virus infectivity and transmission by promoting virus-cell attach-
ment and cell-cell adhesion has been consistently demonstrated
[1,5–7]. In this study we further show that HIV-1 itself is capable
of stimulating LFA-1 and converting it to an active conformation
that allows binding to ICAM-1 with high affinity. The functional
evidence was provided in the glass-supported planar bilayer system
in which we observed that the interaction of HIV-1 envelope
gp120 with fully quiescent, naı ¨ve CD4 T cells enabled stable
interaction of LFA-1 on the T cell surface with ICAM-1 on the
bilayer. In the absence of gp120, naı ¨ve T cells rarely adhered to
ICAM-1. Interestingly, gp120 binding to the naı ¨ve CD4 T cells
also triggered the rearrangement of LFA-1-ICAM-1 interactions
creating an adhesive ring around a central gp120 accumulation,
reminiscent of the pSMAC and c-SMAC structures commonly
found in the T cell receptor-induced immunological synapse. The
same patterns of gp120 and ICAM-1 supramolecular structures
were observed when the activated CD4 T cells interacted with
gp120 on the planar bilayers [25,26]. The ability of gp120 to
activate LFA-1 was further evidenced by the increased sensitivity
of quiescent T cells upon interaction with surface-bound gp120 to
LtxA, a bacterial leukotoxin known to preferentially kill leukocytes
bearing the active form of LFA-1 [28]. gp120-induced LFA-1
activation is likely to promote the formation of the HIV virological
synapse, which is a structure at the cell-cell junction created by the
tight adhesion of LFA-1-ICAM-1 [9,10,25,26,30,31] The forma-
tion of a symmetrical LFA-1-ICAM-1 ring in particular indicates
that cell migration is arrested [26] to allow formation of a stable
cell-cell conjugate which facilitates efficient HIV transfer from
infected cells to new target cells in a protected compact
environment. Beyond the initial virus-cell interaction, it remains
unclear to what extent gp120-induced LFA-1 activation contrib-
utes to a heighten state of immune activation commonly observed
during chronic HIV infection.
The molecular mechanisms for gp120-induced LFA-1 activa-
tion are not fully understood. The data presented here show that
gp120 binding to CD4 is crucial for LFA-1 activation, as antibody
or other compounds that block gp120-CD4 interaction prevented
cell contact with ICAM-1 and nullified the enhanced susceptibility
of the cells to LtxA. The involvement of the chemokine receptor,
on the other hand, is still unclear. The antibody against V3, which
is critical for gp120 interaction with the chemokine receptor,
caused only partial inhibition of ICAM-1 contact. The anti-V3
antibody and chemokine receptor antagonists had minimal effects
on LtxA susceptibility of cells that interacted with gp120. In
previous studies, gp120 binding to CD4 on activated CD4 T cells
also induced formation of supramolecular rearrangement charac-
terized with a central gp120 cluster and a peripheral LFA/ICAM
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blocked by antibodies to the CD4-binding site but not by anti-
V3 antibodies or the chemokine receptor antagonists. The gp120
protein used in the planar bilayer system is from the dual tropic
strain of HIV-1 DH12, while both R5 gp120 (JRFL) and X4
gp120 (IIIB) proteins were found to be comparable in inducing
enhanced sensitivity to LtxA. Considering that resting and naive T
cells express mainly CXCR4 and no or very low levels of CCR5,
the ability of R5 gp120 to activate LFA-1 suggests that gp120
binding to CD4 is the key factor that mediates this activity.
Consistent with this idea, CD4 cross-linking by antibodies was
able to activate LFA-1 to form ICAM-1 contacts on the bilayers
and cause a detectable increase in the naı ¨ve T cell susceptibility to
LtxA. Nevertheless, the levels of LFA-1 activation detected in the
two assays were not identical. While gp120 induced higher
numbers of CD4 T cells forming LFA-1/ICAM-1 interaction on
the bilayers than the anti-CD4 antibody OKT4, gp120 and
OKT4 increased LtxA susceptibility to comparable extents. This
disparity may be attributed to differences in duration and
sensitivity of the two assays. The LtxA-mediated killing was
measured after an overnight incubation and may not detect
differences in the kinetics and the early stages of LFA-1 activation
triggered by gp120 as compared to OKT4. The bilayer
experiments also provided live images showing that the ability of
gp120 to induce formation of the more stable LFA-1-ICAM-1
adhesion rings was not fully replicated by an anti-CD4 antibody.
Our previous studies showed that gp120 binding to CD4 T cells
triggers intracellular signaling events that initiate from activation
of Src family tyrosine kinase Lck and cascade toward LAT and
PLC-c [25]. Interestingly, antibodies that cross-link CD4 also
stimulate Lck phosphorylation, albeit with a spatio-temporal
pattern distinct from that triggered by gp120 [32,33]. All together,
these data indicate that gp120-CD4 interaction may elicit LFA-1
activation via intracellular signaling unique from that induced by
the anti-CD4 antibody.
Under physiologic conditions, LFA-1 activation is triggered in
naı ¨ve T cells following TCR recognition of the cognate peptide-
MHC complexes in conjunction with costimulation from CD4 and
CD28. TCR clustering rapidly recruits CD4-associated Lck, which
becomes phosphorylated transiently and initiates phosphorylation
ITAMs of the TCR-CD3 complex [18]. ZAP70 and LAT are then
brought into the TCR-CD3 clusters, phosphorylated, and in turn
recruit SLP76-Nck-Vav complex, PLC-c, PI3K, and ITK. These
TCR-proximal signaling events generate the second messengers
that propagate the signals downstream to activate transcription
factors such as NFAT and NFkB resulting in upregulation of gene
expression. LFA-1 activation is triggered via the so-called ‘‘inside
out’’ signaling pathway that starts from Vav at the LAT complex
and propagates through PKC, ADAP, and SKAP55 to the
integrin-associated signaling complex that includes PKD, Rap1,
and talin, and then to RAPL and RIAM to result in increased
adhesion of the LFA-1 ectodomain for its ICAM-1 ligand [15]. It
is not known if the same LFA-1 activation pathway is triggered by
gp120; however, CD4 T cell interaction with gp120 on the planar
bilayers has been shown to cause recruitment and phosphorylation
of Lck and downstream signaling molecules CD3f, ZAP70, LAT,
SLP76 and PLCc [25]. Activation of these signaling molecules
indicates that gp120-induced signaling events are likely transduced
downstream to the LAT/SLP76 activation complex to reach Vav,
although the recruitment and activation of Vav have not been
directly demonstrated. Nevertheless, the activity of LFA-1-
targeting LtxA against CD4 T cells exposed to gp120 is much
less potent than that against CD4 T cells fully activated by anti-
CD3/CD28 antibodies, indicating that gp120-induced LFA-1
activation is dissimilar either qualitatively or quantitatively from
that by the T cell receptor-induced stimuli. This observation is
consistent with previous data showing that gp120 induces
incomplete signaling that does not propagate beyond PLC-c and
fails to trigger Ca
2+ flux [25].
While gp120-induced LFA-1 activation may be beneficial for
the virus, we may also be able to take advantage of this activity as
an anti-viral strategy. Hence, we present here for the first time the
activity of LFA-1-targeting leukotoxin LtxA against CD4 T cells
recently exposed to the HIV envelope and CD4 T cells supporting
active HIV infection. Both cell types display activated phenotypes
with enhanced levels of LFA-1 on the cell surface and thus are
more susceptible to killing by LtxA. Importantly, the enhanced
susceptibility to LtxA is exhibited by CD4 T cells interacting with
surface-bound gp120 and not by cells simply exposed to soluble
gp120 monomers that may be shed from the virus. Because LtxA
targets an invariant cellular protein LFA-1 [28], the activity of
LtxA is not affected by the tremendous genetic, biologic, and
antigenic variation of HIV-1. Therefore, LtxA-based approach to
eradicate HIV-infected cells differs from previously reported
strategies of utilizing toxin-conjugated CD4 or antibodies that
target productively infected cells via the virus envelope antigens
[34,35], which are not only highly variable but are also occluded
to various degrees in the vast majority of HIV-1 clinical isolates.
This strategy is also different from previously reported studies of
utilizing LFA-1 antagonists that are aimed to reduce the efficiency
of virus-cell interaction and suppress virus transmission [36]. LtxA
kills activated CD4 T cells by an apoptotic mechanism as
demonstrated by Annexin V upregulation [37]. LtxA may be
administered in a short course along with ART. Previous studies
demonstrate that three doses of LtxA to leukemic mice were
sufficient to eliminate the malignancy and result in long-term
disease-free progression [28]. The short-course administration of
LtxA should reduce the risk of severe immunosuppression as
reported with the clinical use of Efalizumab, a monoclonal
antibody against the CD11a subunit of LFA-1 for treatment of
Figure 4. (A) CD4 T cells bearing HIV p24 antigen express higher levels of total LFA-1 on the surface. Ex vivo PBMCs from two viremic
HIV-infected subjects (PS05 with 38,165 vRNA copies/ml and PS07 with 35,201 vRNA copies/ml) were stained with mAbs for surface expression of
CD3, CD8, and total LFA-1, as well as for intracellular p24 antigen after permeabilization. The cells were subjected to flow cytometric analyses, and the
data analyzed by the FlowJo software. The dot plots (top) show the percentages of p24+ cells among CD4 T cells (CD3+ CD8-) from subjects PS05 and
PS07. The p24+ gating were determined based on p24 staining of HIV-seronegative PBMCs (Fig. S3). The histograms (bottom) compare LFA-1
expression on p24+ and p24- CD4 T cells; the mean fluorescence intensity (mfi) for p24+ and p24- CD4 T cells are 462 and 376 for PS05, and 311 and
228 for PS07. (B) Expression of active LFA-1 on p24+ versus p24- CD4 T cells. PBMCs from viremic HIV-infected subjects (PS15 with 5,075 vRNA copies/
ml and PS16 with 7,077 vRNA copies/ml) were stained with mAb NKI-L16 and secondary fluorescent anti-mouse antibodies, followed with direct
staining with fluorescent mAbs to CD3, CD8 and p24. The histograms compare mAb NKI-L16 staining on p24+ and p24- CD4 T cells; the mfi for p24+
and p24- cells are 405 and 95 for PS15 and 835 and 86 for PS16. p24+ CD4 T cells treated with the secondary antibody (no NKI-L16) were also shown
for control (mfi=19 and 18). (C) Reduction of viral DNA in HIV-infected PBMCs due to LtxA cytotoxicity. PBMCs from two viremic HIV-infected subjects
(PS05 with 38,165 vRNA copies/ml and CD4 count of 814 and PS14 with 21,815 vRNA copies/ml and CD4 count of 494) were treated with LtxA
(7.8 mg/ml) for 20 hrs. The viral DNA were quantified by real time PCR with the specific primers. Averages and standard deviation from epeat
experiments are presented. Statistical analysis was done by one-sided Student’s t test.
doi:10.1371/journal.pone.0023202.g004
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,50 copies/ml, the virus often still replicates at low levels in
infected CD4 T cells and other cell types [39,40] and intermittent
transient viremia are also frequently detected in well suppressed
HIV-infected subjects on ART [39,41,42]. Such viral blips are
thought to result from activation of latently-infected cells by
antigen recognition or bystanders in a local inflammatory response
[43], suggesting that LtxA treatment may be effective against these
activated cells. Nevertheless, LtxA is not likely to eradicate latent
HIV reservoirs in resting CD4 T cells or other cell types that do
not express high levels of activated LFA-1. LtxA also may have
unintended effects on uninfected LFA-1-bearing leukocytes
including virus-specific T cells needed for controlling HIV
infection. Moreover, HIV infection has been consistently associ-
ated with increased numbers of activated uninfected bystander
CD4 and CD8 T lymphocytes [44,45], and this may pose a serious
challenge in developing LtxA for an HIV therapeutic drug as these
cells are likely more susceptible to LtxA. Future studies are needed
to investigate this possibility in order to fully appreciate the
potential of LtxA as an anti-HIV therapeutic agent.
In summary, this study demonstrates for the first time the ability
of HIV envelope gp120 to directly induce LFA-1 activation on
CD4 T cells in a CD4-dependent mechanism. LFA-1 activation
on target and infected CD4 T cells may enhance HIV infectivity
and transmission by promoting virus binding and cell-to-cell
spread, but it also increases the cell susceptibility to a bacterial
toxin, LtxA that preferentially targets active LFA-1. This finding
opens a possibility to exploit this LFA-1-targeting leukotoxin as an
anti-HIV agent for reducing or clearing virus burden in HIV-
infected subjects.
Materials and Methods
Cells
PBMCs from healthy donors were isolated from leukopacs,
which were purchased from the New York Blood Center; these
blood donors were anonymous. PBMCs from HIV-infected
subjects were from whole blood; all HIV-infected subjects
recruited for this study gave written informed consent. The New
York University Institutional Review Board approved the use of
human specimens for this study. After Ficoll-Paque Plus
centrifugation, PBMCs were used directly in the experiments or
were first enriched for CD4 T cells using a negative-selection
magnetic bead kit (Miltenyi Biotech or StemCell Tech) as
described previously [25].
Leukotoxin (LtxA)
LtxA was purified from culture supernatants of A. actinomyce-
temcomitans strain NJ4500 as previously described [46,47]. Protein
was lyophilized in sterile vials and stored at 280uC. Samples were
reconstituted in sterile distilled water and filtered through a
0.22 mm filter prior to use. When prepared in this manner, LtxA
was stable for at least 6 months.
Planar bilayer assay and microscopy
Planar bilayers were prepared as described previously [25,26]
from liposomes containing 12.5% Ni
2+-chelating DOGS-NTA
(1,2-dioleoyl-sn-glycero-3-[N(5-amino-1-carboxypentyl) iminodia-
cetic acid] succinyl and glycosylphosphatidylinositol (GPI)-an-
chored or His12-tagged Cy5-labeled mouse ICAM-1 (density of
200-250 molecules/mm
2). His6-gp120 of HIV-1 DH12 used to
reconstitute the bilayers was produced from recombinant vaccinia
virus [48], labeled with Alexa Fluor 488 (Invitrogen), and applied
onto the bilayers at a concentration that resulted in gp120 density
of 200 to 250 molecules/mm
2. After the flow cell containing the
bilayers was warmed to 37uC, cells were injected and images
collected for 1 hr on a wide-field fluorescence microscope. To test
the effects of anti-gp120 mAbs, bilayers were first treated for
20 min with 20 mg/ml of each mAb (EH21, 2219, and 654). The
cells were also suspended in buffer containing 20 mg/ml of the
mAb before injection to the bilayers. Bilayers containing anti-CD4
and anti-CD3 antibodies were also prepared as previously
described [25,26], using monobiotinylated and Alexa Flour 488
labeled anti-CD3e (OKT3) or anti-CD4 (OKT4) monoclonal
antibodies from eBioscience. OKT3 and OKT4 were applied onto
the bilayers at 250 molecules/mm
2, a density comparable to that of
gp120. The densities of these molecules were determined at each
experiment by coating the same bilayer preparations onto 5 mm
silica beads and analyzing the beads by flow cytometry using
fluorescein calibration beads.
Multicolor fluorescence microscopy was performed on an
automated microscope with an Orca-ER cooled charge-couple-
devise (CCD) camera or electron multiplier CCD camera
(Hamamatsu). The hardware on the microscope was controlled
using Scanalytics IP-Lab software on a Dell personal computer.
Solamere Technology provided integration support. Image
processing and analyses were performed with IP Lab and
Metamorph software. TIRF microscopy was performed either
on an Olympus IX70 or a Nikon Eclipse Ti microscope with either
a Hamamatsu Orca-ER CCD or an Andor iXon 897 EMCCD
camera. Nikon TIRF microscopy images were flat-field corrected
using ImageJ 1.45b.
Flow cytometric analysis
Surface and intracellular staining of PBMCs was done as
previously described [49]. Fluorescence-conjugated antibodies to
CD3 (APC-Cy7) and CD8 (APC) were used to gate CD4 T cell
population (CD3+ CD8-) studied, and FITC-conjugated anti-p24
monoclonal antibody (KC57; Coulter) was used to detect CD4 T
cells with active HIV replication. Total LFA-1 expression was
measured with PE-conjugated anti-CD11a mAb (BD Pharmin-
gen), while active LFA-1 was detected with mAb NKI-L16, which
was a generous gift from Drs. C. Figdor and B. Joosten (Radboud
University Nijmegen Medical Centre, Nijmegen, The Nether-
lands) [29]. Data analyses were done with the FlowJo software
(Tree Star).
Cell viability assay
CD4 T cells (1610
5/well) were added to microtiter wells pre-
coated with wild type, mutant, or no gp120 (10 mg/ml) and then
treated with LtxA at the designated concentrations. Soluble gp120
was added to the cells at 10 mg/ml. For comparison, cells activated
with anti-CD3/anti-CD28 (5 mg/ml each) or anti-CD4 (10 mg/ml)
antibodies on microtiter wells were also treated with LtxA. In some
experiments, cells were incubated on gp120-coated wells in the
presence of anti-gp120 monoclonal antibodies (20 mg/ml), soluble
CD4 (20 mg/ml), or chemokine receptor antagonists (10 mM). The
culture medium contained RPMI, 10% fetal bovine serum, L-
glutamine, and penicillin/streptomycin. After 20 hrs, cellular
viability after LtxA treatment was determined using the CellTi-
ter-Glo luminescent cell viability assay (Promega). Plates were read
in Perkin Elmer Victor3 Multilabel Counter in the luminescence
mode.
Real-time PCR
Cells were lysed by incubation with lysis buffer (5 mM Tris
[pH 8.3], 0.45% Triton X-100, 0.45% Tween 20) and proteinase
K (20 mg/ml) for 1 hr at 60uC and then for 15 min at 95uCt o
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20 ml reaction on the Applied Biosystems 7900HT Fast Real-Time
PCR System with 1X SYBR Green Supermix (SYBR Green I
Dye, AmpliTaq GoldH DNA Polymerase, dNTPs with dUTP,
passive reference dye, and optimized buffer components) (Applied
Biosystems) and the specific primers (5 picomoles each). For
measuring gag, a 115-bp fragment in the gag region was amplified
using the primers SK38 (59-ATAATCCACCTATCCCAGTAG-
GAGAAAT-39) and SK39 (59-TTTGGTCCTTGTCTTATGTC-
CAGAATGC-39) (Invitrogen) [50] under the following reaction
condition: 95uC for 10 min (initial denaturation) and 40 cycles of
95uC for 15 sec (denaturation) and 60uC for 1 min (primer
annealing and extension). For b-actin, a 217 bp fragment was
amplified using primers 59-CTCCATCCTGGCCTCGCTGT-39
and 59-CACCTTCACCGTTCCAGTTT-39 in the following
reaction condition: 95uC for 10 min (initial denaturation) and 40
cycles of 95uC for 30 sec (denaturation), 55uC for 30 sec (primer
annealing), 60uC for 1 min (primer extension). PCR products were
quantified based on the standard curve in each experiment. The
8E5 LAV cells, each of which contains 1 copy of HIV provirus and
2 copies of b-actin gene, were used to generate the standard
curves.
Supporting Information
Figure S1 Surface phenotype of naı ¨ve CD4 T cells
enriched from PBMCs of HIV-seronegative donors.
Naı ¨ve CD4 T cells were enriched by negative selection with
antibody-coated magnetic beads and then treated with fluorescent
antibodies to CD3, CD4 (A), CD45RA, and CD45RO (B). C)
These naive cells were also stained with mAb NKI-L16 which
detects an epitope present specifically in the active state, extended
conformation of LFA-1 a chain (left panel). Whole PBMCs stained
with NKI-L16 are shown for comparison (right panel).
(TIF)
Figure S2 A) The background p24 staining of CD4 T
cells (CD3+ CD8-) from a HIV-seronegative donor,
NG05. This gating was used to determine positive p24 staining
in the CD4 T cells of HIV-seropositive subjects. B) CD3
expression on p24+ and p24- CD4 T cell populations from
HIV-infected subjects PS05 and PS07. The mfi for p24+ and p24-
cells are 87 and 85 for PS05, and 74 and 61 for PS07.
(TIF)
Figure S3 Measurement of b-actin copy numbers in
HIV-infected PBMCs after LtxA treatment. PBMCs from
two viremic HIV-infected subjects (PS05 with 38,165 vRNA
copies/ml and CD4 count of 814 and PS14 with 21,815 vRNA
copies/ml and CD4 count of 494) were treated with LtxA (7.8 mg/
ml) for 20 hrs. The b-actin copy numbers were quantified by real
time PCR with the specific primers. Averages and standard
deviation from 4 repeat experiments are presented.
(TIF)
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